The findings, published April 22 in The Lancet Respiratory Medicine, showed a booster dose was about 80 percent to 90 percent effective at preventing hospital admissions and emergency department visits caused by delta and omicron within three months of receiving the shot. After three months, protection against hospitalization caused by omicron fell to about 55 percent, while protection against ED visits that did not result in hospitalization fell to 53 percent.
The study used Kaiser Permanente patient records from December 2021 through Feb. 6, 2022. Researchers analyzed 11,123 hospital admissions and ED visits that did not result in admission for acute respiratory infection.
“Pfizer BioNTech COVID-19 booster doses significantly improve protection against omicron, although that protection seems to wane after three months against emergency room visits, and even for hospitalization,” said Sara Tartof, PhD, lead study author and epidemiologist at the health system’s department of research and evaluation in Southern California. “Trends in waning against delta-related outcomes were generally similar to omicron but with higher effectiveness at each time point than those seen for omicron.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
